Eli Lilly's Zepbound reduces type 2 diabetes risk, study shows

Group 1 - Eli Lilly's weight-loss drug, tirzepatide, significantly reduces the risk of developing type 2 diabetes by 94% in overweight patients with pre-diabetes compared to a placebo [1][2] - The treatment leads to sustained weight loss, with patients on the highest dose experiencing an average body weight decrease of 22.9% [1] - The study involved 1,032 adults over a three-year period [1] Group 2 - Obesity affects nearly 900 million adults globally, increasing the risk of complications like type 2 diabetes [2] - Eli Lilly's second-quarter earnings exceeded Wall Street expectations, with $11.3 billion in global revenue compared to the expected $9.92 billion [3] - Adjusted earnings per share were reported at $3.92, surpassing the anticipated $2.60 [3] Group 3 - Tirzepatide was first approved for type 2 diabetes treatment under the brand name Mounjaro in 2022 [4] - In November 2023, the injection was approved for adults with obesity or those with weight-related medical issues, marketed as Zepbound [4]